Entero’s 1-for-3 Reverse Split Sparks 25% Stock Surge, Registers 4.9M Shares for Resale

Entero Therapeutics Inc Overview

Entero Therapeutics Inc (NASDAQ: ENTO) is a late clinical-stage biopharmaceutical company focused on developing targeted, orally delivered therapies for gastrointestinal (GI) diseases. Following its rebranding in May 2024, the company has concentrated its pipeline on three proprietary technologies—latiglutenase, capeserod, and adrulipase—targeting conditions including celiac disease, gastroparesis, and exocrine pancreatic insufficiency.

Corporate Structure and Workforce

Founded in 2014 and headquartered in Boca Raton, Florida, Entero employs between 11 and 50 individuals. The workforce comprises scientists, clinicians, and regulatory professionals specializing in non-systemic GI therapies. Richard Paolone is the Interim Chief Executive Officer, leading the company through various corporate and regulatory milestones to support its Nasdaq listing and clinical development strategy.

Gastrointestinal therapies by Deon Black

Recent Developments and News

• May 16, 2024: The company completed a business combination with ImmunogenX and rebranded from First Wave BioPharma to Entero Therapeutics, adopting the ticker symbol ENTO.
• November 13, 2024: Entero entered into a binding term sheet for a proposed reverse merger with Journey Therapeutics, Inc., intending to combine Journey’s nano-immunoconjugate oncology platform with Entero’s GI pipeline.
• August 14, 2025: Entero announced a 1-for-3 reverse stock split, effective August 18, 2025, to meet Nasdaq Capital Market minimum bid-price requirements under Rule 5550(a)(2).
• September 9, 2025: The company filed a Current Report on Form 8-K, detailing corporate governance updates and ongoing operational matters.
• September 10, 2025: Entero filed an amendment on Form S-1/A registering 4,945,510 shares of common stock for resale by certain selling stockholders, including 1,626,282 shares issuable upon exercise of pre-funded warrants and 3,319,228 shares issuable upon exercise of common warrants.

Financial and Strategic Analysis

As of the September 12, 2025 market close, Entero’s stock price was $2.88, reflecting a 25.22% increase on a trading volume of 203,734 shares. The reverse split reduced outstanding shares from approximately 4.77 million to 1.59 million, which may assist in compliance with per-share price standards. The recent Form S-1/A enables existing warrant holders to liquidate positions, while the company may receive cash proceeds from warrant exercises, facilitating ongoing R&D and clinical activities.

The company’s strategic initiatives include:

• Progressing latiglutenase into a Phase 3 celiac disease trial expected to initiate in early 2025, following consultations with the FDA regarding its clinical plan.
• Advancing capeserod in Phase 2 studies for multiple GI indications, utilizing its selective 5-HT4 receptor partial agonist activity.
• Conducting Phase 2 trials of adrulipase, a recombinant lipase enzyme indicated for exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

Market Position and Industry Context

Entero addresses unmet needs in the GI therapeutics market, where approved treatment options for celiac disease, gastroparesis, and exocrine pancreatic insufficiency are limited. Its non-systemic, oral biotherapeutics differentiate it from systemically administered medications. The market for celiac disease alone represents a significant commercial opportunity, with no current approved pharmacologic treatments available. Strategic partnerships and potential licensing agreements could enhance Entero’s competitive positioning.

tl;dr

On August 18, 2025, Entero executed a 1-for-3 reverse split to maintain Nasdaq compliance. Two days later, the company filed Form S-1/A registering nearly 5 million shares for resale by warrant holders. As of September 12, 2025, ENTO shares traded at $2.88 (+25.22%). Entero plans to initiate a Phase 3 trial of latiglutenase in early 2025 and continues clinical development of capeserod and adrulipase.